Delving into the Latest Updates on PXS-6302 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Topical pan-LOX inhibitor-Pharmaxis

Target

lipoxygenase

Action

inhibitors

Mechanism

lipoxygenase inhibitors(Lipoxygenase inhibitors)

Therapeutic Areas

Other Diseases

Active Indication

Cicatrix

Inactive Indication-

Originator Organization

Syntara Ltd.

Active Organization

Syntara Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Author: Chaudhari, Nutan ; Findlay, Alison D ; Joshi, Amar ; Jarolimek, Wolfgang ; Stevenson, Andrew W ; Hortin, Nicole ; Rea, Suzanne ; Toshniwal, Priyanka ; Fear, Mark W ; Clemons, Tristan D ; Melton, Philip E ; Iyer, K Swaminathan ; Sayyar, Sepidar ; Wood, Fiona M ; Wallace, Gordon ; Deng, Zhenjun ; Yao, Yimin

AbstractScarring is a lifelong consequence of skin injury, with scar stiffness and poor appearance presenting physical and psychological barriers to a return to normal life. Lysyl oxidases are a family of enzymes that play a critical role in scar formation and maintenance. Lysyl oxidases stabilize the main component of scar tissue, collagen, and drive scar stiffness and appearance. Here we describe the development and characterisation of an irreversible lysyl oxidase inhibitor, PXS-6302. PXS-6302 is ideally suited for skin treatment, readily penetrating the skin when applied as a cream and abolishing lysyl oxidase activity. In murine models of injury and fibrosis, topical application reduces collagen deposition and cross-linking. Topical application of PXS-6302 after injury also significantly improves scar appearance without reducing tissue strength in porcine injury models. PXS-6302 therefore represents a promising therapeutic to ameliorate scar formation, with potentially broader applications in other fibrotic diseases.

100 Deals associated with PXS-6302

Login to view more data